Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma

Sorafenib, systemic treatment for advanced hepatocellular carcinoma (HCC), and regorafenib, novel second line treatment after sorafenib failure, have efficacy limited by evasive mechanisms of acquired-drug resistance. BCL-2 proteins participate in the response to tyrosine kinase inhibitors; however,...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Tutusaus, Anna, Stefanovic, Milica, Boix, Loreto, Cucarull, Blanca, Zamora, Aynara, Blasco, Laura, de Frutos, Pablo García, Reig, Maria, Fernandez-Checa, Jose C., Marí, Montserrat, Colell, Anna, Bruix, Jordi, Morales, Albert
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2018
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5908280/
https://ncbi.nlm.nih.gov/pubmed/29682179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24673
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items